1. Molecular subtyping for clinically defined breast cancer subgroups.

    Breast Cancer Research (Online Edition) 17(1):520 (2015) PMID 25778358 PMCID PMC4365540

    Breast cancer is commonly classified into intrinsic molecular subtypes. Standard gene centering is a routinely done prior to molecular subtyping but can produce inaccurate classifications when the distribution of clinicopathological characteristics in the study cohort differs from that of the tr...
  2. Collaborative regression.

    Biostatistics 16(2):326 (2015) PMID 25406332 PMCID PMC4441100

    We consider the scenario where one observes an outcome variable and sets of features from multiple assays, all measured on the same set of samples. One approach that has been proposed for dealing with these type of data is "sparse multiple canonical correlation analysis" (sparse mCCA). All of th...
  3. Collaborative regression.

    Biostatistics 16(2):326 (2015) PMID 25406332

    We consider the scenario where one observes an outcome variable and sets of features from multiple assays, all measured on the same set of samples. One approach that has been proposed for dealing with these type of data is "sparse multiple canonical correlation analysis" (sparse mCCA). All of th...
  4. Pancancer analysis of DNA methylation-driven genes using MethylMix.

    Genome biology 16(1):17 (2015) PMID 25631659 PMCID PMC4365533

    Aberrant DNA methylation is an important mechanism that contributes to oncogenesis. Yet, few algorithms exist that exploit this vast dataset to identify hypo- and hypermethylated genes in cancer. We developed a novel computational algorithm called MethylMix to identify differentially methylated ...
  5. Quantitative SD-OCT imaging biomarkers as indicators of age-related macular degeneration progression.

    Investigative Ophthalmology & Visual Science 55(11):7093 (2014) PMID 25301882

    We developed a statistical model based on quantitative characteristics of drusen to estimate the likelihood of conversion from early and intermediate age-related macular degeneration (AMD) to its advanced exudative form (AMD progression) in the short term (less than 5 years), a crucial task to e...
  6. Quantitative SD-OCT Imaging Biomarkers as Indicators of Age-Related Macular Degeneration Progression.

    Investigative Ophthalmology & Visual Science 55(11):7093 (2014) PMID 25301882

    We developed a statistical model based on quantitative characteristics of drusen to estimate the likelihood of conversion from early and intermediate age-related macular degeneration (AMD) to its advanced exudative form (AMD progression) in the short term (less than 5 years), a crucial task to e...
  7. Quantitative SD-OCT imaging biomarkers as indicators of age-related macular degeneration progression.

    Investigative Ophthalmology & Visual Science 55(11):7093 (2014) PMID 25301882

    We developed a statistical model based on quantitative characteristics of drusen to estimate the likelihood of conversion from early and intermediate age-related macular degeneration (AMD) to its advanced exudative form (AMD progression) in the short term (less than 5 years), a crucial task to e...
  8. Quantitative SD-OCT Imaging Biomarkers as Indicators of Age-Related Macular Degeneration Progression.

    Investigative Ophthalmology & Visual Science 55(11):7093 (2014) PMID 25301882

    We developed a statistical model based on quantitative characteristics of drusen to estimate the likelihood of conversion from early and intermediate age-related macular degeneration (AMD) to its advanced exudative form (AMD progression) in the short term (less than 5 years), a crucial task to e...
  9. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

    Journal of Clinical Oncology 32(17):1797 (2014) PMID 24799467 PMCID PMC4039868

    Idiotypes (Ids), the unique portions of tumor immunoglobulins, can serve as targets for passive and active immunotherapies for lymphoma. We performed a multicenter, randomized trial comparing a specific vaccine (MyVax), comprising Id chemically coupled to keyhole limpet hemocyanin (KLH) plus gra...
  10. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

    Journal of Clinical Oncology 32(17):1797 (2014) PMID 24799467 PMCID PMC4039868

    Idiotypes (Ids), the unique portions of tumor immunoglobulins, can serve as targets for passive and active immunotherapies for lymphoma. We performed a multicenter, randomized trial comparing a specific vaccine (MyVax), comprising Id chemically coupled to keyhole limpet hemocyanin (KLH) plus gra...
  11. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

    Journal of Clinical Oncology 32(17):1797 (2014) PMID 24799467 PMCID PMC4039868

    Idiotypes (Ids), the unique portions of tumor immunoglobulins, can serve as targets for passive and active immunotherapies for lymphoma. We performed a multicenter, randomized trial comparing a specific vaccine (MyVax), comprising Id chemically coupled to keyhole limpet hemocyanin (KLH) plus gra...
  12. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

    Journal of Clinical Oncology 32(17):1797 (2014) PMID 24799467 PMCID PMC4039868

    Idiotypes (Ids), the unique portions of tumor immunoglobulins, can serve as targets for passive and active immunotherapies for lymphoma. We performed a multicenter, randomized trial comparing a specific vaccine (MyVax), comprising Id chemically coupled to keyhole limpet hemocyanin (KLH) plus gra...
  13. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.

    British Journal of Haematology 165(3):358 (2014) PMID 24467658 PMCID PMC3990235

    Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare subtype of non-Hodgkin lymphoma (NHL) with limited data on pathology and outcome. A multicentre retrospective study was undertaken to determine prognostic factors and the incidence of central nervous system (CNS) relapses. Data was r...
  14. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.

    British Journal of Haematology 165(3):358 (2014) PMID 24467658 PMCID PMC3990235

    Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare subtype of non-Hodgkin lymphoma (NHL) with limited data on pathology and outcome. A multicentre retrospective study was undertaken to determine prognostic factors and the incidence of central nervous system (CNS) relapses. Data was r...
  15. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.

    British Journal of Haematology 165(3):358 (2014) PMID 24467658 PMCID PMC3990235

    Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare subtype of non-Hodgkin lymphoma (NHL) with limited data on pathology and outcome. A multicentre retrospective study was undertaken to determine prognostic factors and the incidence of central nervous system (CNS) relapses. Data was r...
  16. Increasing value and reducing waste in research design, conduct, and analysis

    The Lancet 383(9912):166 (2014)

    Correctable weaknesses in the design, conduct, and analysis of biomedical and public health research studies can produce misleading results and waste valuable resources. Small effects can be difficult to distinguish from bias introduced by study design and analyses. An absence of detai...
  17. Increasing value and reducing waste in research design, conduct, and analysis.

    The Lancet 383(9912):166 (2014) PMID 24411645

    Correctable weaknesses in the design, conduct, and analysis of biomedical and public health research studies can produce misleading results and waste valuable resources. Small effects can be difficult to distinguish from bias introduced by study design and analyses. An absence of detailed writte...
  18. Increasing value and reducing waste in research design, conduct, and analysis.

    The Lancet 383(9912):166 (2014) PMID 24411645

    Correctable weaknesses in the design, conduct, and analysis of biomedical and public health research studies can produce misleading results and waste valuable resources. Small effects can be difficult to distinguish from bias introduced by study design and analyses. An absence of detailed writte...
  19. Increasing value and reducing waste in research design, conduct, and analysis.

    The Lancet 383(9912):166 (2014) PMID 24411645

    Correctable weaknesses in the design, conduct, and analysis of biomedical and public health research studies can produce misleading results and waste valuable resources. Small effects can be difficult to distinguish from bias introduced by study design and analyses. An absence of detailed writte...
  20. A shared transcriptional program in early breast neoplasias despite genetic and clinical distinctions.

    Genome biology 15(5):R71 (2014) PMID 24887547 PMCID PMC4072957

    The earliest recognizable stages of breast neoplasia are lesions that represent a heterogeneous collection of epithelial proliferations currently classified based on morphology. Their role in the development of breast cancer is not well understood but insight into the critical events at this ear...